Chester County News and Community Website
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) states that the independent Data and Safety Monitoring Board (DSMB) for its Phase 1/2 clinical trial of OCU400, the Company’s flagship modifier gene …
Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that the first patient has been recently dosed in the Phase 1/2 clinical trial of OCU400, a modifier gene therapy candidate for …
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that the first patient has been recently dosed in the Phase 1/2 clinical trial of OCU400, a modifier gene therapy candidate for …
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration Read More